Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Emerging therapies for NASH: an overview of promising targets

Authors: Peiseler M, Schwabe R, Hampe J et al.
Published in TouchREVIEWS in Endocrinology 2022
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 25% of the world’s adult population. In 20% of these patients, NAFLD further develops into non-alcoholic steatohepatitis (NASH), which itself represents a leading cause of progression to liver cirrhosis and hepatocellular carcinoma.
Read More

Effects of mitochondrial transplant therapy on the reparation of injured skeletal muscle

Authors: Alway SE, Paez HG, Pitzer CR et al.
Published in Journal of Cachexia, Sarcopenia and Muscle 2023
It is known that traumatic muscle injury damages mitochondria, which may cause them to leak their contents into the cytoplasm and subsequently trigger calcium accumulation, cell death, endoplasmic reticulum stress, and the release of reactive oxygen species (ROS).
Read More

Daily walking speed and frailty: a significant association?

Authors: Kawai H, Obuchi S, Ejiri M et al.
Published in BMJ 2023
Walking speed (WS) is clinically recognized as a crucial vital sign. Associations between daily walking speed (DWS) and health outcomes have been underscored by a number of studies, which have further recognized it as an accurate predictor of dependency and mortality in elderly individuals. Despite this knowledge, very few studies have examined the link between DWS and frailty.
Read More

A multidisciplinary approach to NAFLD-centred care

Authors: Schattenberg JM, Allen AM, Jarvis H et al.
Published in Communications Medicine 2022
The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) has been well-characterised by recent literature. As such, patients with NAFLD are disproportionately affected by a range of comorbidities, which include obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and hypertension.
Read More

Understanding the clinical benefits of cirrhosis regression in NASH

Authors: Sanyal AJ, Anstee QM, Trauner M et al.
Published in Hepatology 2022
Cirrhosis is the end stage of a number of chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Characterised by the scarring of liver tissue, cirrhosis leads to significant hepatic tissue distortion, which may subsequently cause portal hypertension, hepatic synthetic dysfunction, and hepatocellular carcinoma.
Read More